Login / Signup

Synergistic effects of epoxyazadiradione (EAD) and paclitaxel against triple-negative breast cancer cells.

Kunnathully Sudhan SijishaRajitha AnushaSulochana Priya
Published in: Fundamental & clinical pharmacology (2024)
To conclude, EAD could be the drug of choice for combined treatment with paclitaxel in a chemotherapy regimen.
Keyphrases
  • breast cancer cells
  • locally advanced
  • squamous cell carcinoma
  • cancer therapy
  • combination therapy
  • adverse drug
  • decision making